仑伐替尼靶向PDGFR-β周细胞并抑制其与甲状腺癌细胞协同作用
研究利用新基因特征评估TCGA中甲状腺乳头状癌(PTC)与正常甲状腺的周细胞丰度,并共培养甲状腺来源周细胞与BRAFWT/V600E-PTC细胞。发现BRAFV600E-PTC伴hTERT突变及拷贝数改变者周细胞丰度显著更高,仑伐替尼通过PDGFR-β靶向周细胞,增强共培养中PTC细胞死亡。
要点
- BRAFV600E-PTC伴hTERT突变和拷贝数改变者周细胞丰度显著高于正常甲状腺或BRAFWT-PTC。
- PDGF-BB通过激活p-PDGFR-β、pERK1/2和pAKT促进周细胞生长。
- 仑伐替尼靶向周细胞PDGFR-β,增强共培养中BRAFWT/V600E-PTC细胞死亡。
核心结论
- 首次建立甲状腺特异性模型,证明仑伐替尼通过靶向周细胞PDGFR-β抑制BRAFWT/V600E-PTC生长。
- 评估PTC患者周细胞丰度可能对仑伐替尼靶向治疗选择至关重要。
研究设计与样本
- 利用新基因特征评估TCGA中PTC和正常甲状腺样本的周细胞相对丰度。
- 共培养CD90+;PAX8-甲状腺来源周细胞与BRAFWT/V600E-PTC来源细胞,检测旁分泌通讯及仑伐替尼反应。
主要发现
- BRAFV600E-PTC伴hTERT突变和拷贝数改变者周细胞丰度显著高于正常甲状腺或BRAFWT-PTC,校正临床病理混杂因素后仍显著。
- 鉴定出与肿瘤生存、免疫调节、RNA转录、细胞周期调控和胆固醇代谢相关的上调通路。
- PDGF-BB显著增加周细胞生长,激活p-PDGFR-β、pERK1/2和pAKT。
- 仑伐替尼通过下调PDGFR-β下游MAPK、pAKT和p-p70S6激酶强烈抑制周细胞活力。
- 仑伐替尼通过靶向周细胞PDGFR-β,在共培养中显著诱导更高BRAFWT/V600E-PTC细胞死亡。
临床怎么用
- PTC患者可评估周细胞丰度,作为仑伐替尼靶向治疗选择的参考依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Pericyte populations abundantly express tyrosine kinases (eg, platelet-derived growth factor receptor-β [PDGFR-β]) and impact therapeutic response. Lenvatinib is a clinically available tyrosine kinase inhibitor that also targets PDGFR-β. Duration of therapeutic response was shorter in patients with greater disease burden and metastasis. Patients may develop drug resistance and tumor progression. OBJECTIVES: Develop a gene signature of pericyte abundance to assess with tumor aggressiveness and determine both the response of thyroid-derived pericytes to lenvatinib and their synergies with thyroid carcinoma-derived cells. DESIGN: Using a new gene signature, we estimated the relative abundance of pericytes in papillary thyroid carcinoma (PTC) and normal thyroid (NT) TCGA samples. We also cocultured CD90+;PAX8- thyroid-derived pericytes and BRAFWT/V600E-PTC-derived cells to determine effects of coculture on paracrine communications and lenvatinib response. RESULTS: Pericyte abundance is significantly higher in BRAFV600E-PTC with hTERT mutations and copy number alterations compared with NT or BRAFWT-PTC samples, even when data are corrected for clinical-pathologic confounders. We have identified upregulated pathways important for tumor survival, immunomodulation, RNA transcription, cell-cycle regulation, and cholesterol metabolism. Pericyte growth is significantly increased by platelet-derived growth factor-BB, which activates phospho(p)-PDGFR-β, pERK1/2, and pAKT. Lenvatinib strongly inhibits pericyte viability by down-regulating MAPK, pAKT, and p-p70S6-kinase downstream PDGFR-β. Critically, lenvatinib significantly induces higher BRAFWT/V600E-PTC cell death when cocultured with pericytes, as a result of pericyte targeting via PDGFR-β. CONCLUSIONS: This is the first thyroid-specific model of lenvatinib therapeutic efficacy against pericyte viability, which disadvantages BRAFWT/V600E-PTC growth. Assessing pericyte abundance in patients with PTC could be essential to selection rationales for appropriate targeted therapy with lenvatinib.
引用
- Iesato A, Li S, Roti G, et al. Lenvatinib Targets PDGFR-β Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. J Clin Endocrinol Metab. 2021. PMID: 34302727. doi:10.1210/clinem/dgab552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。